Guardant Health, Inc. (NASDAQ:GH) is one of the best growth stocks to buy according to billionaires.

As of March 13, 2026, Guardant Health carried a Moderate Buy consensus from 23 analysts, based on 21 Buy ratings, one Hold, and one Sell. The average 12-month price target stood at $122.57, implying about 43% upside from the recent share price of $85.49, while the published target range ran from $55 to $180.

The bullish tone came after a stretch of company updates that gave analysts more to work with than a single earnings print. On February 19, 2026, Guardant Health reported fourth-quarter 2025 revenue of $281.3 million, up 39% year over year, with oncology revenue rising 30% to $189.9 million and screening revenue reaching $35.1 million. The company said it expects total 2026 revenue to grow 27% to 30%.

Tonhom1009/Shutterstock.com

Management then added more detail at the Leerink Global Healthcare Conference on March 10, 2026, and the Barclays 28th Annual Global Healthcare Conference on March 11, 2026. At those events, Guardant highlighted its Quest Diagnostics partnership as a key commercial lever for Shield and said any upside from Quest’s co-promotion was not included in 2026 guidance. The company also said 90% of Shield users had not been screened in the prior five years, reinforcing its view that Shield can expand the screening market rather than just compete within it. Management also pointed to further portfolio catalysts, including potential FDA-related progress tied to ESR1 monitoring in Guardant360, while noting that Reveal Ultra was excluded from 2026 guidance because reimbursement remains uncertain.

Against that backdrop, Piper Sandler analyst David Westenberg maintained a Buy rating and $130 price target on March 11, 2026, after raising his target from $120 to $130 on February 24, 2026, following the company’s quarterly release.

Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company that develops blood-based tests for cancer screening, treatment selection, and recurrence monitoring.

While we acknowledge the potential of GH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News.